Every material Form 8-K Protagonist Therapeutics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Protagonist Therapeutics reported third-quarter 2025 results on November 6, 2025. The net loss widened to $39.3 million, or $0.62 per share, from $33.2 million, or $0.54 per share, a year earlier, as research and development expense rose to $40.0 million while license and collaboration revenue stayed flat at $4.7 million. The company said cash, cash equivalents and marketable securities of $678.8 million at September 30, 2025 are expected to fund operations through at least the end of 2028.
Q3 2025 license and collaboration revenue was $4.7 million, unchanged from $4.7 million in Q3 2024.
Q3 2025 research and development expense was $40.0 million, up from $36.0 million; general and administrative expense was $11.1 million.
Nine-month net loss was $85.8 million, compared with net income of $143.5 million in the same period of 2024.
Cash, cash equivalents and marketable securities were $678.8 million at September 30, 2025, with runway stated as through at least end of 2028.
Protagonist Therapeutics reported its second quarter 2025 results, with license and collaboration revenue of $5.5 million, up from $4.2 million a year earlier, while its net loss widened to $34.8 million, or $0.55 per share, from $30.6 million, or $0.50 per share. Cash, cash equivalents and marketable securities totaled $673.0 million at June 30, 2025, which the company expects to fund operations through at least the end of 2028.
Q2 2025 license and collaboration revenue was $5.5 million, compared with $4.2 million in Q2 2024, all from development services under the Takeda collaboration.
Q2 2025 net loss was $34.8 million, or $0.55 per basic and diluted share, versus a net loss of $30.6 million, or $0.50 per share, in Q2 2024.
Cash, cash equivalents and marketable securities were $673.0 million at June 30, 2025, up from $559.2 million at December 31, 2024.
Icotrokinra NDA for plaque psoriasis was filed with the FDA in July 2025; the rusfertide U.S. NDA for polycythemia vera is expected in Q4 2025.
Protagonist Therapeutics reported a first-quarter 2025 net loss of $11.7 million, or $0.19 per share, compared with net income of $207.3 million, or $3.41 per basic share, in the first quarter of 2024. License and collaboration revenue fell to $28.3 million from $255.0 million, as the prior-year period included most of the Takeda upfront payment. Cash, cash equivalents and marketable securities rose to $697.9 million, which the company expects to fund operations through at least the end of 2028.
License and collaboration revenue was $28.3 million, versus $255.0 million in Q1 2024; $22.8 million reflects a $25 million milestone earned in Q1 2025 but payable after the VERIFY clinical study report.
Net loss was $11.7 million, or $0.19 per basic and diluted share, compared with net income of $207.3 million in Q1 2024.
Cash, cash equivalents and marketable securities were $697.9 million at March 31, 2025, up from $559.2 million at December 31, 2024.
Rusfertide Phase 3 VERIFY data is scheduled for an oral presentation at the ASCO plenary session on June 1, 2025.
Protagonist Therapeutics reported fourth-quarter and full-year 2024 results. Net income was $131.7 million, or $2.11 per basic share, in the fourth quarter, up from $27.3 million a year earlier, and $275.2 million for 2024, compared with a net loss of $79.0 million in 2023. The company said its cash position, including a $165.0 million milestone payment received in January 2025, should fund operations through at least the end of 2028.
Q4 2024 license and collaboration revenue was $170.6 million, versus $60.0 million in Q4 2023.
Full-year 2024 license and collaboration revenue was $434.4 million, versus $60.0 million in 2023, mainly from the Takeda agreement and the JNJ milestones.
Cash, cash equivalents and marketable securities were $559.2 million as of December 31, 2024, compared with $341.6 million a year earlier.
Topline results from the Phase 3 VERIFY rusfertide trial and the Phase 2b ANTHEM icotrokinra trial are expected in March 2025.
Effective January 1, 2025, Suneel Gupta, Ph.D., transitioned from Chief Development Officer to Executive Vice President, Clinical Development at Protagonist Therapeutics. The filing is a role change for a senior executive, and it does not disclose financial results, compensation terms, or a new hire.
Effective date of the change: January 1, 2025
Suneel Gupta, Ph.D., moved from Chief Development Officer to Executive Vice President, Clinical Development
The filing was signed by Chief Financial Officer Asif Ali on January 6, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Protagonist Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →